Supplementary Figure 1B from Wnt/β-Catenin Signaling Regulates Cytokine-Induced Human Inducible Nitric Oxide Synthase Expression by Inhibiting Nuclear Factor-κB Activation in Cancer Cells

Supplementary Figure 2B from Wnt/β-Catenin Signaling Regulates Cytokine-Induced Human Inducible Nitric Oxide Synthase Expression by Inhibiting Nuclear Factor-κB Activation in Cancer Cells

Modern cholangioscopy systems have been used for targeted evaluation and management of pancreaticobiliary diseases since 2007 (1). Its use has been limited to targeted evaluation and management of pancreaticobiliary diseases (2). We present a novel use of cholangioscopy system to assess and biopsy a high grade malignant duodenal stricture. A 42 year old male with past medical history of gastroesophageal reflux disease presented as a transfer from an outside hospital with gastric outlet obstruction secondary to an obstructing duodenal ulcer noted on upper endoscopy. Patient had initially presented with intractable nausea, vomiting, and a 20 pounds unintentional weight loss over a two week period. Biopsies from the gastric antrum resulted positive for Helicobacter pylori and biopsies from the duodenal ulcer only showed inflammatory cells. He was admitted to the outside hospital for antibiotics, nasogastric tube decompression and total parenteral nutrition. With minimal clinical improvement, patient was transferred to our facility where repeat upper endoscopy showed an obstructing duodenal ulcer (Figure 1). This was not traversable using scopes between 34 Fr to 16 Fr in size, despite dilating this stricture with a 12 mm TTS balloon over a 0.035 inch guidewire under fluoroscopy. Cholangioscopy system was then utilized which allowed visualization of a 6 cm, circumferential, malignant appearing stricture from the proximal second portion of duodenum to distal third portion of duodenum which was friable, ulcerated and edematous (Figure 2). Biopsies using cholangioscopy forceps returned positive for invasive adenocarcinoma (Figure 3). CT scan of the chest, abdomen and pelvis obtained for staging purposes demonstrated no convincing evidence of metastatic disease. Patient subsequently underwent an uncomplicated, standard pancreaticoduodenectomy with retroperitoneal lymphadenectomy. Modern cholangioscopy systems have been used for the evaluation and management of pancreaticobiliary diseases. We demonstrate an alternative application of cholangioscopy systems in assessing a high grade malignant duodenal stricture.Figure: Obstructing Duodenal Ulcer on Endoscopy.Figure: Duodenal Stricture on Cholangioscopy System.Figure: Pathology consistent with Duodenal Adenocarcinoma.

A 50-year-old woman with a history of uncomplicated Crohn's disease presented for esophagogastroduodenoscopy (EGD) for evaluation of acute epigastric pain, nausea, and bilious vomiting.EGD revealed retained food in the stomach and what appeared to be a large, approximately 2-cm obstructing gallstone in the duodenal bulb (Figure 1).After multiple instruments failed to retrieve the gallstone, a needle knife was utilized to break the gallstone into pieces that were then retrieved using a Roth net.After removal of the gallstone, a suspected cholecystoduodenal fistula was seen.An emergent computed tomography of the abdomen confirmed a fistulous tract between the gallbladder and duodenum (Figure 2).Endoscopic retrograde cholangiopancreatography (ERCP) demonstrated contrast extravasating from the gallbladder into the duodenum.Biliary sphincterotomy was performed with the placement of a 10 Fr x 5 cm plastic biliary stent in the common bile duct.An additional stone that was impacted within the cholecystoduodenal fistula was removed successfully using a stone-extracting balloon (Figure 3).An endoscopic suturing device was utilized to place one endoscopic suture, resulting in complete closure of the fistula (Figure 4).The patient subsequently underwent uncomplicated, open cholecystectomy with no fistula seen during surgery.

Chronic renal impairment causes profound physiologic and metabolic changes. Its impact on surgical outcome after pancreatectomy is not well established. We sought to quantify complication rates of pancreatectomy in patients with chronic renal impairment. Database from the American College of Surgeons National Surgical Quality Improvement Project (2005–2011) was queried to identify patients with chronic renal impairment who underwent pancreatectomy. The study population consisted of 16,708 patients of whom 16,649 patients were not on dialysis and 59 patients were on dialysis. Overall mortality for those on dialysis was 5.1 per cent, whereas it was 2.3 per cent for those not on dialysis ( P = 0.114). Patients on dialysis were more likely to have failure to wean ventilation ( P < 0.001), reintubation ( P = 0.004), myocardial infarction ( P = 0.007), and sepsis ( P = 0.046). Patients not on dialysis were then divided into three groups: serum creatinine levels <1.2 mg/dL, between 1.2 mg/dL and 2.0 mg/dL, and >2.0 mg/dL. We found the mortality rates for these three groups were 2.0 per cent, 4.6 per cent, and 7.5 per cent, respectively ( P < 0.001). In conclusion, need for dialysis is associated with increased postoperative complications. Increased serum creatinine levels were associated with increased mortality rates. These findings should facilitate informative risk/benefit calculation for patients with renal impairment who are considering pancreatectomy.

Myelolipomas are rare tumors consisting of both adipose and hematopoietic tissue and are typically found within the adrenal gland. Extra-adrenal involvement is rare, especially those tumors involving the perirenal space and collecting system. We report a case of a patient with an incidentally discovered perirenal mass that was initially concerning for a retroperitoneal liposarcoma. Following surgical resection and pathological analysis, the lesion was found to be an extra-adrenal myelolipoma. This case report and review of the literature demonstrates the importance of the proper work-up and management of perirenal lipoma variants while addressing the issues of tissue biopsy, surgical intervention, and pre- and post-operative surveillance.

Background The extracellular release of the danger signal high mobility group box-1 (HMGB1) has been implicated in the pathogenesis and outcomes of sepsis. Understanding the mechanisms responsible for HMGB1 release can lead to the identification of targets that may inhibit this process. The transcription factor interferon regulatory factor-1 (IRF-1) is an important mediator of innate immune responses and has been shown to participate in mortality associated with endotoxemia; however, its role in mediating the release of HMGB1 in these settings is unknown.Methods Male IRF-1 knockout (KO) and age matched C57BL/6 wild type (WT) mice were given intraperitoneal (IP) injections of lipopolysaccharide (LPS). In some experiments, 96 hours survival rates were observed. In other experiments, mice were sacrificed 12 hours after LPS administration and sera were harvested for future analysis. In in vitro study, RAW 264.7 murine monocyte/macrophage-like cells or primary peritoneal macrophage obtained from IRF-1 KO and WT mice were cultured for LPS mediated HMGB1 release analysis. And the mechanism for HMGB1 release was analyzed by immune-precipitation.Results IRF-1 KO mice experienced less mortality, and released less systemic HMGB1 compared to their WT counterparts. Exogenous administration of recombinant HMGB1 to IRF-1 KO mice returned the mortality rate to that seen originally in IRF-1 WT mice. Using cultures of peritoneal macrophages or RAW264.7 cells, in vitro LPS stimulation induced the release of HMGB1 in an IRF-1 dependent manner. And the Janus associated kinase (JAK)-IRF-1 signal pathway appeared to participate in the signaling mechanisms of LPS-induced HMGB1 release by mediating acetylation of HMGB1.Conclusion IRF-1 plays a role in LPS induced release of HMGB1 and therefore may serve as a novel target in sepsis.

Objectives: This study aimed to compare survival outcomes after hepatic resection (HR) and radiofrequency ablation (RFA) in early-stage hepatocellular carcinoma (HCC) at a Western hepatobiliary centre. Methods: Demographic details, clinicopathologic tumour characteristics and survival outcomes were compared among non-transplant candidate patients undergoing HR (n= 50) and RFA (n= 60) for early-stage HCC during 20012011. Results: Patients who underwent HR had larger tumours, a longer length of stay and a higher rate of postoperative complications. After a median follow-up of 29months, there were no significant differences between the treatment groups in 1-, 3- and 5-year overall survival (OS) [RFA group: 86%, 50%, 35%, respectively; HR group: 88%, 68%, 47%, respectively (P= 0.222)] or disease-free survival (DFS) [RFA group: 68%, 42%, 28%, respectively; HR group: 66%, 42%, 34%, respectively (P= 0.823)]. The 58 patients who underwent RFA demonstrated ablation success on follow-up computed tomography at 3months. Of these, 96.5% of patients showed sustained ablation success over the entire follow-up period. In a subgroup analysis of patients with tumours measuring 25cm, no differences in OS or DFS emerged between the HR and RFA groups. Similarly, no significant differences in outcomes in patients with ChildPugh class A cirrhosis were seen between the RFA and HR groups. Conclusions: Radiofrequency ablation is comparable with HR in terms of OS and DFS. It is a reasonable alternative as a first-line treatment for HCC in well-selected patients who are not candidates for transplant.

Introduction: Hepatic ischemia/reperfusion (I/R) occurs in multiple clinical settings and involves activation of innate immunity, cytokine production, and release of endogenous danger signals such as HMGB1. the mechanisms that account for inflammation and local organ damage are only partially understood but include deranged calcium signaling and activation of Ca+2/Calmodulin Dependent Kinases (CaMK). the purpose of this study was to investigate the contribution of the CaMK II isoform to this process during liver I/R. Methods: WT, NADPH oxidase deficient (p47KO), or WT mice treated with the CaMKII inhibitor, AC3I, were subjected to partial warm ischemia of the left and median lobes of the liver. Liver damage was measured by serum ALT. Serum HMGB1 and tissue CaMKII activation determined by Western blot. HMGB1 localization was analyzed by immunofluorescent staining. in vitro, primary cell cultures were treated with AC3I or antioxidant and exposed to hypoxia (1% O2) or hydrogen peroxide (H2O2). Results: in vivo, hepatic I/R resulted in increased CaMKII activation. CaMKII inhibition with AC3I treatment resulted in protection from liver damage compared to vehicle treated control animals as measured by circulating ALT levels. Inhibition of CaMKII also resulted in decreased circulating levels of HMGB1 compared to controls. Using immunofluorescent staining, we found that hepatocytes of AC3I treated mice also demonstrated decreased HMGB1 nucleo-cytoplasmic translocation compared to control mice (Figure). to determine if the mechanism of CaMKII activation in liver I/R was mediated by oxidative stress, p47KO or WT mice treated with the antioxidant NAC were used. Both p47KO and WT mice treated with NAC were found to have decreased CaMKII activation compared to controls. in vitro, CaMKII activation was observed in hepatocyte and non-parenchymal cell (NPC) co-cultures exposed to hypoxia or H2O2. NPC cultures treated with AC3I and exposed to hypoxia had decreased inflammatory cytokine release compared to control cells. Transfer of cell culture media from oxidative-stressed NPCs to hepatocytes resulted in HMGB1 translocation and release, and this effect was abrogated by CaMKII inhibition in NPCs. Conclusions: CaMKII is activated during hepatic I/R and promotes organ damage through release of proinflammatory cytokines by NPCs and release of HMGB1 from hepatocytes. in addition, the activation of CaMKII occurs in response to NADPH oxidase-mediated oxidative stress. Inhibition of CaMKII leads to liver protection and therefore represents a potential therapeutic option against I/R injury.

Hypoxia is often found in solid tumors and is associated with tumor progression and poor clinical outcomes. The exact mechanisms related to hypoxia-induced invasion and metastasis remain unclear. We elucidated the mechanism by which the nuclear-damageassociated molecular pattern molecule, high-mobility group box 1 (HMGB1), released under hypoxic stress, can induce an inflammatory response to promote invasion and metastasis in hepatocellular carcinoma (HCC) cells. Caspase-1 activation was found to occur in hypoxic HCC cells in a process that was dependent on the extracellular release of HMGB1 and subsequent activation of both Toll-like receptor 4 (TLR4)- and receptor for advanced glycation endproducts (RAGE)-signaling pathways. Downstream from hypoxia-induced caspase-1 activation, cleavage and release of proinflammatory cytokines interleukin (IL)-1 beta and -18 occurred. We further demonstrate that overexpression of HMGB1 or treatment with recombinant HMGB1 enhanced the invasiveness of HCC cells, whereas stable knockdown of HMGB1 remarkably reduced HCC invasion. Moreover, in a murine model of HCC pulmonary metastasis, stable knockdown of HMGB1 suppressed HCC invasion and metastasis. Conclusion: These results suggest that in hypoxic HCC cells, HMGB1 activates TLR4- and RAGE-signaling pathways to induce caspase-1 activation with the subsequent production of multiple inflammatory mediators, which, in turn, promote cancer invasion and metastasis. (HEPATOLOGY 2012;55:18661875)

Interferon regulatory factor (IRF)-1 is a nuclear transcription factor that induces inflammatory cytokine mediators and contributes to hepatic ischemia-reperfusion (I/R) injury. No strategies to mitigate IRF1-mediated liver damage exist. IRF2 is a structurally similar endogenous protein that competes with IRF1 for DNA binding sites in IRF-responsive target genes and acts as a competitive inhibitor. However, the role of IRF2 in hepatic injury during hypoxic or inflammatory conditions is unknown. We hypothesize that IRF2 overexpression may mitigate IRF1-mediated I/R damage. Endogenous IRF2 is basally expressed in normal livers and is mildly increased by ischemia alone. Overexpression of IRF2 protects against hepatic warm I/R injury. Furthermore, we demonstrate that IRF2 overexpression limits production of IRF1-dependent proinflammatory genes, such as IL-12, IFNβ, and inducible nitric oxide synthase, even in the presence of IRF1 induction. Additionally, isograft liver transplantation with IRF2 heterozygote knockout (IRF2(+/-)) donor grafts that have reduced endogenous IRF2 levels results in worse injury following cold I/R during murine orthotopic liver transplantation. These findings indicate that endogenous intrahepatic IRF2 protein is protective, because the IRF2-deficient liver donor grafts exhibited increased liver damage compared with the wild-type donor grafts. In summary, IRF2 overexpression protects against I/R injury by decreasing IRF1-dependent injury and may represent a novel therapeutic strategy.

The pathogenesis of sepsis is complex and, unfortunately, poorly understood. The cellular process of autophagy is believed to play a protective role in sepsis; however, the mechanisms responsible for its regulation in this setting are ill defined. In the present study, interferon regulatory factor 1 (IRF-1) was found to regulate the autophagic response in lipopolysaccharide (LPS)-stimulated macrophages. In vivo, tissue macrophages obtained from LPS-stimulated IRF-1 knockout (KO) mice demonstrated increased autophagy and decreased apoptosis compared to those isolated from IRF-1 wild-type (WT) mice. In vitro, LPS-stimulated peritoneal macrophages obtained from IRF-1 KO mice experienced increased autophagy and decreased apoptosis. IRF-1 mediates the inhibition of autophagy by modulating the activation of the mammalian target of rapamycin (mTOR). LPS induced the activation of mTOR in WT peritoneal macrophages, but not in IRF-1 KO macrophages. In contrast, overexpression of IRF-1 alone increased the activation of mTOR and consequently decreased autophagic flux. Furthermore, the inhibitory effects of IRF-1 mTOR activity were mediated by nitric oxide (NO). Therefore, we propose a novel role for IRF-1 and NO in the regulation of macrophage autophagy during LPS stimulation in which IRF-1/NO inhibits autophagy through mTOR activation.

Sepsis-induced lymphocyte and dendritic cell apoptosis contributes to immunosuppression, which results in an inability to eradicate the primary infection as well as a propensity to acquire new, secondary infections. Another cellular process, autophagy, is also activated in immune cells and plays a protective role. In the present study, we demonstrate that interferon regulatory factor 1 (IRF-1) regulates both immune cell apoptosis and autophagy in a murine endotoxemia model. Interferon regulatory factor 1 is activated at an early phase through a Toll-like receptor 4-dependent, myeloid differentiation primary response gene 88-independent manner in splenocytes. Furthermore, IRF-1 knockout (KO) mice are protected from a lethal endotoxemia model. This protection is associated with decreased apoptosis and increased autophagy in splenocytes. Interferon regulatory factor 1 KO mice experience decreased apoptotic cell loss, especially in CD4(+) T lymphocytes and myeloid antigen-presenting cells. Meanwhile, IRF-1 KO mice demonstrate increased autophagy and improved mitochondrial integrity. This increased autophagy in KO mice is attributable, at least in part, to deactivation of mammalian target of rapamycin/P70S6 signaling-a main negative regulator of autophagy. Therefore, we propose a novel role for IRF-1 in regulating both apoptosis and autophagy in splenocytes in the setting of endotoxemia with IRF-1 promoting apoptosis and inhibiting autophagy.

Sterile inflammatory insults, such as ischemia-reperfusion (I/R) injury, result from pathogenic factors, including damage-associated molecular pattern signaling, activation of innate immunity, and upregulation of proinflammatory cytokines. At the same time, a number of protective, or prosurvival, pathways are also activated, and the extent of end-organ damage is ultimately determined by the balance between these two systems. In liver I/R, members of the calcium/calmodulin-dependent protein kinase (CaMK) family are known to be activated, but their individual roles are largely unknown. In this study, we show that one CaMK member, CaMKIV, is protective in hepatic I/R by activating the prosurvival pathway of autophagy in hepatocytes. CaMKIV knockout mice experience significantly worse organ damage after I/R and are deficient in hepatocyte autophagic signaling. Restoration of autophagic signaling with rapamycin reduces organ damage in CaMKIV knockout mice to wild-type levels. In vitro, we show that CaMKIV activation induces autophagy in mouse hepatocytes, and that CaMKIV activation protects hepatocytes from oxidative stress-induced cell death. In conclusion, the protective autophagic signaling pathway serves to reduce organ damage following I/R and is regulated by activation of CaMKIV signaling in hepatocytes.

Concomitant increasing incidences of hepatocellular carcinoma (HCC) and nonalcoholic steatohepatitis (NASH) suggest that a substantial proportion of HCC arises as a result of hepatocellular injury from NASH. The aim of this study was to determine differences in severity of liver dysfunction at HCC diagnosis and long‐term survival outcomes between patients undergoing curative therapy for HCC in the background of NASH compared to hepatitis C virus (HCV) and/or alcoholic liver disease (ALD). Patient demographics and comorbidities, clinicopathologic data, and long‐term outcomes among patients who underwent liver transplantation, hepatic resection, or radiofrequency ablation for HCC were reviewed. From 2000 to 2010, 303 patients underwent curative treatment of HCC; 52 (17.2%) and 162 (53.5%) patients had NASH and HCV and/or alcoholic liver disease. At HCC diagnosis, NASH patients were older (median age 65 versus 58 years), were more often female (48.1% versus 16.7%), more often had the metabolic syndrome (45.1% versus 14.8%), and had lower model for end‐stage liver disease scores (median 9 versus 10) (all P < 0.05). NASH patients were less likely to have hepatic bridging fibrosis or cirrhosis (73.1% versus 93.8%; P < 0.001). After a median follow‐up of 50 months after curative treatment, the most frequent cause of death was liver failure. Though there were no differences in recurrence‐free survival after curative therapy (median, 60 versus 56 months; P = 0.303), NASH patients had longer overall survival (OS) (median not reached versus 52 months; P = 0.009) independent of other clinicopathologic factors and type of curative treatment. Conclusion: Patients with HCC in the setting of NASH have less severe liver dysfunction at HCC diagnosis and better OS after curative treatment compared to counterparts with HCV and/or alcoholic liver disease. (HEPATOLOGY 2012;55:1811–1821)

Despite detection on imaging before resection of hepatic malignancies, the natural history of indeterminate pulmonary nodules (IPN) is unknown. The objective of this study is to determine how often IPN detected on imaging before surgery for hepatic malignancies represent lung metastases.

Background: Trauma/Hemorrhagic shock (T/HS) induced gut injury is known to initiate a dysfunctional inflammatory response leading to secondary lung injury. Our group has shown that vagal nerve stimulation (VNS) protects the intestinal epithelial integrity, attenuates inflammatory cytokine formation, and protects the lung after a thermal insult. We hypothesize that VNS will protect the lung from injury following trauma/hemorrhagic shock.Methods: Male Balb/c mice were subjected to a trauma/hemorrhagic shock model (mean arterial pressure of 35 mmHg for one hour), with and without right cervical vagal nerve stimulation. A cohort of animals underwent abdominal vagotomy (Vx) at the gastro-esophageal junction prior to vagal nerve stimulation and trauma/hemorrhagic shock. Lung histology (H&E), myeloperoxidase (MPO) and ICAM-1 immuno-staining, and MPO enzymatic assay were analyzed 24 hours post-shock …

Reactive oxygen species (ROS) contribute to the development of interstitial fibrosis and tubular atrophy seen in chronic allograft nephropathy (CAN). As molecular hydrogen gas can act as a scavenger of ROS, we tested the effect of treatment with hydrogen water (HW) in a model of kidney transplantation, in which allografts from Lewis rats were orthotopically transplanted into Brown Norway recipients that had undergone bilateral nephrectomy. Molecular hydrogen was dissolved in water and recipients were given HW from day 0 until day 150. Rats that were treated with regular water (RW) gradually developed proteinuria and their creatinine clearance declined, ultimately leading to graft failure secondary to CAN. In contrast, treatment with HW improved allograft function, slowed the progression of CAN, reduced oxidant injury and inflammatory mediator production, and improved overall survival. Inflammatory signaling pathways, such as mitogen-activated protein kinases, were less activated in renal allografts from HW-treated rats as compared with RW-treated rats. Hence, oral HW is an effective antioxidant and antiinflammatory agent that prevented CAN, improved survival of rat renal allografts, and may be of therapeutic value in the setting of transplantation.

The mobilization and extracellular release of nuclear high mobility group box-1 (HMGB1) by ischemic cells activates inflammatory pathways following liver ischemia/reperfusion (I/R) injury. In immune cells such as macrophages, post-translational modification by acetylation appears to be critical for active HMGB1 release. Hyperacetylation shifts its equilibrium from a predominant nuclear location toward cytosolic accumulation and subsequent release. However, mechanisms governing its release by parenchymal cells such as hepatocytes are unknown. In this study, we found that serum HMGB1 released following liver I/R in vivo is acetylated, and that hepatocytes exposed to oxidative stress in vitro also released acetylated HMGB1. Histone deacetylases (HDACs) are a family of enzymes that remove acetyl groups and control the acetylation status of histones and various intracellular proteins. Levels of acetylated HMGB1 increased with a concomitant decrease in total nuclear HDAC activity, suggesting that suppression in HDAC activity contributes to the increase in acetylated HMGB1 release after oxidative stress in hepatocytes. We identified the isoforms HDAC1 and HDAC4 as critical in regulating acetylated HMGB1 release. Activation of HDAC1 was decreased in the nucleus of hepatocytes undergoing oxidative stress. In addition, HDAC1 knockdown with siRNA promoted HMGB1 translocation and release. Furthermore, we demonstrate that HDAC4 is shuttled from the nucleus to cytoplasm in response to oxidative stress, resulting in decreased HDAC activity in the nucleus. Together, these findings suggest that decreased nuclear HDAC1 and HDAC4 activities in hepatocytes following liver I/R is a mechanism that promotes the hyperacetylation and subsequent release of HMGB1.

Introduction: Release of the danger signal, high mobility group box 1 (HMGB1), mediates the inflammatory response following hepatic ischemia-reperfusion (I/R) injury. Post-translational acetylation of HMGB1 is required for the active secretion of HMGB1. Since oxidative stress induces calcium signaling, we sought to determine if the calcium/calmodulin-dependent protein kinase (CaMK) IV pathway modulated HMGB1 acetylation and subsequent release during liver I/R. Methods: Cultured mouse hepatocytes from CaMKIV WT and KO mice were exposed to hypoxia (1% O2). Western blotting, immunofluorescence, RT-PCR, and activity assays were performed for CaMKIV activation, histone deacetylase (HDAC) activity, and HMGB1 release. For in vivo studies, a murine model of warm partial liver I/R was utilized. Results: Hepatocyte CaMKIV is activated by oxidative stress with increased phosphylation of CaMKIV in cultured hepatocytes exposed to hypoxia and in vivo during liver I/R. Interestingly, CaMKIV KO mice subjected to liver I/R experienced worsened liver damage (ALT: KO - 3372 vs. WT - 2125,p<0.05) and higher circulating HMGB1 levels compared to their wild type counterparts. To determine the mechanism of CaMKIV protection during ischemic liver injury, we examined whether CaMKIV mediated the deacetylation and subsequent blockage of nucleocytoplasmic shuttling and release of HMGB1 through HDACs, a family of enzymes responsible for removing acetyl groups from histones and other nuclear proteins. Co-immunoprecipitation experiments revealed that HMGB1 is a substrate for the HDAC isoform, HDAC1, in hepatocytes undergoing oxidative stress. Furthermore, in hypoxic hepatocytes, HDAC1 activity is decreased compared to normoxic controls and targeted knockdown of HDAC1 with siRNA increased the release of acetylated HMGB1. Similarly in vivo, increased circulating acetylated HMGB1 was associated with decreased hepatic HDAC1 activity during I/R. CaMKIV was found to regulate HDAC1 as CaMKIV KO hepatocytes exposed to hypoxic conditions had a further decrease in HDAC1 phosphorylation and released more acetylated HMGB1 compared to WT cells. Conclusions: Our findings indicate that CaMKIV prevents oxidant-induced HMGB1 release in hepatocytes through the regulation of HDAC1 activity. HDAC1 promotes nuclear retention of HMGB1 by decreasing the acetylated form of HMGB1. These results indicate that CamKIV may play a protective role in liver during ischemic stress by counterbalancing the inflammatory signals that promote the release of the danger signal HMGB1.